mTOR signaling pathway and mTOR inhibitors in cancer therapy

Alejandro Gomez-Pinillos; Anna C Ferrari

doi:10.1016/j.hoc.2012.02.014

mTOR signaling pathway and mTOR inhibitors in cancer therapy

Hematol Oncol Clin North Am. 2012 Jun;26(3):483-505, vii. doi: 10.1016/j.hoc.2012.02.014. Epub 2012 Mar 31.

Authors

Alejandro Gomez-Pinillos¹, Anna C Ferrari

Affiliation

¹ Department of Medicine, NYU Cancer Institute, New York University School of Medicine, 160 East 34th Street, 8th Floor, New York, NY 10016, USA.

PMID: 22520976
DOI: 10.1016/j.hoc.2012.02.014

Abstract

Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase. It is ubiquitously expressed in cells and is a therapeutic target for the cancer treatment arsenal. Despite the great responses obtained in tumors addicted to specific mutations or overactivation of key members of the mTOR pathway (HiF1α in RCC, cyclin D1 in MCL, or TSC in SEGA), mTOR inhibitors as single agents have modest activity. Dual PI3K/mTOR kinase inhibitors have been developed with the idea of overcoming resistance to the mTOR inhibition through preventing the activation of PI3K/Akt as a result of release negative feedback loops.

Publication types

Review

MeSH terms

Humans
Neoplasms / drug therapy*
Neoplasms / metabolism*
Protein Kinase Inhibitors / therapeutic use*
Signal Transduction / drug effects
TOR Serine-Threonine Kinases / antagonists & inhibitors*
TOR Serine-Threonine Kinases / metabolism*

Substances

Protein Kinase Inhibitors
MTOR protein, human
TOR Serine-Threonine Kinases